Next Generation Humanized Mice for AML and NK Cell Therapy Testing

Join Amy Wesa, PhD, director of Immuno-Oncology Research at Champions Oncology Inc. discussing the latest advances in human immune system mouse models for oncology therapeutics and more!

next-generation-webinar-with-amy-wesa

To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, will discuss:

  • How complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models
  • The latest advances in human immune system mouse models for oncology therapeutics
  • The power of primary patient-derived models for acute myeloid leukemia (AML)
  • Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice

Register Now!